Related Experiment Video

Updated: Jul 15, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
09:23

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability

Published on: June 21, 2015

Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic

Guo-Xing Li1, Qiu-Ling Pei, Yi Gao

  • 1Tianjin Centers for Disease Control and Prevention, Hedong District, Tianjin, PR China.

Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie
|May 1, 2007
PubMed

Insights

Multidrug resistance-associated protein 2 (Mrp2) facilitates arsenic excretion in rats, protecting liver function. Increased Mrp2 expression correlates with higher arsenic levels in bile, suggesting a protective role against arsenic toxicity.

Area of Science:

  • Toxicology
  • Molecular Biology
  • Hepatology

Background:

  • Arsenic poses significant risks to human health.
  • Biliary excretion of organic anions is mediated by the multidrug resistance-associated protein 2 (Mrp2).
  • Mrp2's in vivo role in arsenic excretion and liver protection remains unclear.

Purpose of the Study:

  • To investigate Mrp2's role in in vivo arsenic excretion.
  • To determine Mrp2's protective effects on liver function following arsenic exposure.

Main Methods:

  • Western blot analysis for Mrp2 protein levels in rat liver.
  • Hydride generation atomic absorption spectrometry for total arsenic in blood and bile.
  • Biochemical assays for liver function markers (ALT, AST, GSH-PX, MDA, bilirubin).
  • Electron microscopy for bile canaliculi morphology.

Main Results:

  • Arsenic exposure significantly increased total arsenic levels in blood and bile.
  • Mrp2 protein expression was significantly overexpressed in arsenic-treated rats.
  • A positive correlation was observed between Mrp2 expression and biliary arsenic concentration.
  • Liver function markers indicated damage, worsening with decreased Mrp2 expression.
  • Electron microscopy revealed bile canaliculi damage.

Conclusions:

  • Overexpression of Mrp2 enhances biliary excretion of arsenic.
  • Mrp2 plays a protective role in mitigating arsenic-induced liver damage.
  • Targeting Mrp2 could be a strategy for managing arsenic toxicity.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Phase II Reactions: Miscellaneous Conjugation Reactions01:19

Phase II Reactions: Miscellaneous Conjugation Reactions

Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...